AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03539484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: In the event obinutuzumab treatment is implemented, obinutuzumab will be administered either on Day-7 or on Day-7 and Day-6. If obinutuzumab is given only on one day, then the schedule for Day-7 should be followed including an end of infusion sample.
Study NCT03539484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab was administered if required, for the management of severe CRS (cytokine release syndrome)
Study NCT01443923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Interferon-alfa 2B
Study NCT01443923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT04105842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfilcon A
Description: Participants wear delafilcon A contact lenses on a daily disposable basis.
Study NCT02983461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil, 20mg x 3 times a day for 10 weeks
Study NCT02983461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet, 3 times a day for 10 weeks
Study NCT00264290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: 900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.
Study NCT00264290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo designed to resemble Valganciclovir
Study NCT03403881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity promotion + TAU
Description: Pedometer:~Each patient will receive a pedometer with increasing weekly aims on number of steps during the trial.~The number of steps to be achieved starts on 4.000 and increases progressively until the end of the trial.~Behavioral strategy based on STD theory, and the assessment of barriers and facilitators of each patient.~All patients were receiving treatment as usual
Study NCT03403881 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Weekly call on general health aspects + treatment as usual
Study NCT02547909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: probe-based Confocal Laser Endomicroscopy
Description: Eligible women will be offered to undergo pCLE examination. Conscious sedation will be offered to all patients, who will choose to receive it or not. pCLE will be done using a standard gastroscope, reaching a distance of 25 cm from the anus, to the level of the rectosigmoid angle.~At this point, 2.5 ml fluorescein 10% will be injected. The pCLE probe (GastroFlex-UHD probe, Mauna Kea tech, Paris, France) will be inserted through the endoscope working channel and images will be recorded from areas suspected of harboring an endometriotic tissue.
Study NCT02547909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio
Study NCT02547909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescein 10%
Study NCT02477436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: * One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.~* Investigational products were administered prior to the sexual intercourse for total 8 weeks.
Study NCT02477436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the placebo.~* Placebos were administered prior to the sexual intercourse for total 8 weeks.
Study NCT01065571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carrageenan
Description: The intervention is the carrageenan-free diet. Supplementary carrageenan capsules will be given to mimic the carrageenan in the normal diet.
Study NCT01065571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention with no-carrageenan diet
Description: The intervention will consist of the no-carrageenan diet.
Study NCT02777424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate
Description: Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S
Study NCT02777424 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Pooled collection of plasma from donors
Study NCT02383251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg
Study NCT02383251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²
Study NCT02383251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²
Study NCT03035669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness group
Description: 8 week program
Study NCT03035669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading group
Description: 8 week program
Study NCT01082237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Start at 5mg per day, after four days increase to 10mg per day for the duration of the study. 20 mg will be administered at week 8 if not significantly better.
Study NCT01079910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isopropylmethylphenol and Fluoride
Description: 0.1% isopropylmethylphenol and 1150ppm fluoride
Study NCT01079910 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluoride and Silica
Description: NaF/Silica toothpaste containing 1150ppm fluoride
Study NCT03200977 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT02749110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling brush
Description: Self-collection by unscreened women aged from 30 to 65 of a vaginal sample with the device. After collection, the whole device is mailed in a normalized for biological samples package to the virology lab of the University Hospital of Lille where a HPV test is conducted using a Cobas 4800 technique.
Study NCT00203268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroergotamine mesylate
Description: 1.0 mg. intramuscularly
Study NCT01655303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study NCT01655303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Study NCT01655303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Study NCT01655303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Study NCT02255071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure wristband
Description: A acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
Study NCT02255071 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham wristband
Description: A wristband over wrist but no acupressure for seven days.
Study NCT00612651 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temodar and SCH 66336
Description: 2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated \& escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle \& escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning \& evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 \& 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.
Study NCT00328575 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy (IMRT)
Description: The duration of radiation therapy will be total of 3 weeks. During the first week, all patients will be treated initially with whole brain radiation therapy (WBRT) at 2.5Gy per fraction daily 5 days a week to a dose of 12.5Gy. This will be delivered through parallel-opposed fields to cover the entire cranial contents.~For the remaining 2 weeks, patients will be treated using intensity-modulated radiation therapy (IMRT) technology such that a higher dose can be delivered to the tumor. IMRT is capable of generating complex 3-D dose distribution to conform closely to the target volume by modulating the radiation beam. This process is based on the inverse method of treatment planning to optimize radiation dose to tumor target coverage and normal tissue sparing.
Study NCT02683408 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive placebo
Study NCT02683408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diosmiplex
Description: diosmiplex is an FDA regulated medical food product
Study NCT02429102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554
Study NCT02429102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02704650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluid sample
Description: taking a vaginal fluid sample
Study NCT02784288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neck Dissection
Description: All patients will undergo neck dissection of the cervical lymph nodes
Study NCT02784288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard-of-Care (SOC) Transoral Surgery of Primary Site
Description: Patients with a single lymph node that measures less than six centimeters, have no extracapsular extension in the lymph node, and have no perineural or perivascular invasion of the primary biopsy will undergo transoral surgery of the primary site.
Study NCT02784288 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SOC Radiation
Description: Patients who have 2 positive nodes with no extracapsular extension, or have perineural or perivascular invasion of the primary biopsy will undergo radiation.
Study NCT02784288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC Carboplatin
Description: Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
Study NCT02784288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC Paclitaxel
Description: Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
Study NCT05803681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capacitive Coupled Electric Fields (CCEF)
Description: In the CCEF Group, patients received, as an adjunct to the clinical study protocol, CCEF stimulation (Osteospine®, IGEA SpA, Carpi, Italy) 8 h/die for sixty days.
Study NCT05803681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Calssic clinical protocol
Description: (1) bed rest for the first twenty-five days and subsequent mobilization with a three-point hyperextension brace; (2) antiresorptive therapy (75 mg risedronate tablet weekly); (3) supplemental calcium carbonate with 1000 mg of elemental calcium daily if needed based on serum calcium concentration; (4) Vitamin D (≤500 IU daily) if the serum 25-hydroxyvitamin D concentration at the time of screening was below 16 ng/ml). Analgesic therapy with paracetamol 1000mg tablets was assumed for seven days and further depending on pain intensity; patients were required to report on a specific sheet paracetamol assumption.
Study NCT02544165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine intake
Description: The subjects of this group should intake 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
Study NCT02544165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cigarette smoking
Description: The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
Study NCT02544165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine intake and Cigarette smoking
Description: The subjects of this group should smoke one cigarette and should consume 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
Study NCT02514551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02514551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Administered IV
Study NCT02514551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV
Study NCT02514551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered IV
Study NCT02786472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Bystander Training
Description: Large groups of 120-150 students will complete Haven training via computer; training lasts duration of the online program.
Study NCT02786472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Substance Abuse Training
Description: Large groups of 120-150 students will complete EverFi training via computer; training lasts duration of the online program.
Study NCT02786472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Bystander Training
Description: In-person training of large groups of 120-150 students; training lasts 3-4 hours
Study NCT02786472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Combination Training
Description: In-person training of large groups of 120-150 students; training lasts 3-4 hours
Study NCT02727569 — intervention group
Intervention type: DEVICE
Intervention: New visual field algorithm with DLS
Description: Mathematical model (software based) to derive retinal sensitivity.
Study NCT02727569 — intervention group
Intervention type: DEVICE
Intervention: SITA algorithm
Description: Mathematical model (software based) to derive retinal sensitivity. Commercially available.
Study NCT02727569 — intervention group
Intervention type: DEVICE
Intervention: New visual field algorithm with MMDT
Description: Mathematical model (software based) to derive retinal sensitivity.
Study NCT03238963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: Once daily
Study NCT03238963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study NCT03862014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF+KI
Description: Molar with MIH will be treated with SDF+KI
Study NCT03862014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SDF+KI+GIC(SMART)
Description: Molar with MIH will be treated with SDF+KI+GIC(SMART)
Study NCT02592915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Description: Single bolus of clonidine hydrochloride 0.3µg/kg (max 150 µg/kg) administered IV after induction and obtaining a stable anaesthetic level
Study NCT02592915 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Single bolus of physiologic sodium chloride serum administered IV after induction and obtaining a stable anaesthetic level
Study NCT00245960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Study NCT00245960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03197766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: Subcutaneous injection of 15 μg/kg of BMN 111 daily
Study NCT03197766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of 15 μg/kg of placebo daily
Study NCT00614562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA)
Description: NAVA for 72 hours
Study NCT02170545 — intervention group
Intervention type: OTHER
Intervention: Dual Energy Computed Tomography
Description: A Dual Energy Computed Tomography scan will be performed on both upper arms.
Study NCT01836172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YJP-14
Description: An 50% ethanolic extract of Lindera obtusiloba stems
Study NCT02784288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videofluoroscopy
Description: All patients undergo a videofluoroscopy procedure one year after completion of therapy to assess swallowing function.
Study NCT02734862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD101
Description: Intravenous antifungal therapy
Study NCT02734862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: Intravenous antifungal therapy
Study NCT02734862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: oral antifungal therapy
Study NCT04554537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART
Description: A treatment program developed to address specific brain functions found to be crucial for the recovery following brain injury.
Study NCT04554537 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brain Health Workshop
Description: A psychoeducation program designed to provide in depth information to participants about the neuroscience behind their TBI and PTSD and the symptoms and challenges they may experience.
Study NCT01609777 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: SBAR
Description: situation, background, assessment, recommendation
Study NCT01044927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Care
Description: Comparison of the effect of COPD education, self-management instruction, home monitoring with a Health Buddy Telemonitor, pulse oximeter, pedometer and spirometer, and enhanced communication with a study coordinator (cell phone access)
Study NCT01044927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: No intervention was made. Data measurements were taken at 0, 3, 6 and 9 months, as in the active intervention group.
Study NCT05375097 — intervention group
Intervention type: OTHER
Intervention: Erenumab
Description: Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses
Study NCT03697694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500mg of Aronox® >40% polyphenol aronia extract
Description: Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
Study NCT03697694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
Study NCT02387697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards Sapien XT Valve
Description: The device will be implanted in the present study to prevent abdominal venous congestion and to improve the function of the tricuspid valve which is located in the low pressure system in the right heart.
Study NCT00558792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue 370, 70 mL
Description: 70 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
Study NCT00558792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue 370, 80 mL
Description: 80 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
Study NCT00558792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue 370, 90 mL
Description: 90 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
Study NCT02314689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) citrulline
Study NCT02734862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous placebo
Description: normal saline